

**REMARKS**

Claims 18-72 are pending. Claims 23-27, 36-38, and 40-42 have been withdrawn from consideration. Claims 18-22, 28-35, 39, and 43-45 are under examination. Claims 18, 19, 23, 24, 40, and 41 have been amended based on the Examiner's recommendations. The amendments serve to clarify the claimed invention and do not limit the claims. Claims 46-72 have been added and are directed to particular species of interest, as supported in the specification. No new matter has been added.

**Obviousness-type Double Patenting Rejection**

Claim 18 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,096,713. Although applicants disagree with the double patenting rejection, a terminal disclaimer over U.S. Patent No. 6,096,713 is attached in an effort to expedite prosecution.

**Claim Rejections under 35 U.S.C. § 112, first paragraph**

Claims 18, 19, 21, 22, 28-35, and 39 are rejected under 35 U.S.C. § 112, first paragraph. Claim 18 has been amended as recommended by the examiner.

Claim 18, as amended, includes the language, *inter alia*, "...R", taken together with the carbonyl group of tryptophan represents an imide, an ester, or an anhydride...". The prior claim included the language "an amide". This amendment is a clarification of the prior claim and is not limiting. In view of the clarifying amendment, Applicants respectfully request that this rejection be withdrawn.

**Claim Rejections under 35 U.S.C. § 112, second paragraph**

Claims 18-22, 28-35, 39, and 43-45 are rejected under 35 U.S.C. § 112, second paragraph. Claims 18 and 19 have been amended as recommended by the examiner. This amendment is a clarification of the prior claim and is not limiting. In view of the clarifying amendment, Applicants respectfully request that this rejection be withdrawn.

**Claim Rejections under 35 U.S.C. § 103**

Claims 18, 19, 21, 22, 28-35, and 39 are rejected under 35 U.S.C. § 103 over Haber (Prog. Biochem. Pharmacol. (1976), 12 (Drugs Affecting Renin-Angiotensin-Aldosterone Syst., Prc. Kanematsu Conf. Kidney, 5<sup>th</sup>), 16-32) in view of Rodgers (U.S. Patent No. 5,716,935).

Claims 18, 19, 21, 22, 28-35, and 39 are rejected under 35 U.S.C. § 103 over Haber (Prog. Biochem. Pharmacol. (1976), 12 (Drugs Affecting Renin-Angiotensin-Aldosterone Syst., Prc. Kanematsu Conf. Kidney, 5<sup>th</sup>), 16-32) in view of Rodgers (U.S. Patent No. 5,716,935), further in view of Folkman (J Natl Cancer Inst 82, 4-6, 1990).

Haber describes that EWPRFQIPP inhibits angiotensin-converting enzyme (ACE). The peptide EWPRFQIPP does not anticipate or suggest the claimed invention as currently presented. Applicants respectfully request that the rejection be withdrawn.

Applicants appreciate the Examiner's finding that claim 20, and 43-45 are free of the prior art. In view of the amendments and arguments above, Applicants believe that all of the claims are now allowable.


Applicants note the comments in the Office Action regarding the Information Disclosure Statement submitted May 2, 2002. Reference AT is attached. Applicants request an Examiner-initialled PTO-1449, including documents AT, AU, and AW, be returned to Applicants.

#### CONCLUSION

Applicants believe the application to be in condition for allowance, and respectfully request notice thereof at an early date. If any issues remain, the Examiner is encouraged to telephone the undersigned at the below-listed number.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Sherry M. Party  
Registration No. 51,534

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(919) 941-9240

Date: Oct. 2, 2003

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS EXPRESS MAIL NUMBER EV171050440US, IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA., 22313-1450, ON:

Date: October 2, 2003

By:   
Sandra B. Paye

Thursday, October 26, 1995

8:30 Poster Viewing and Coffee

9:00 Chairperson's Opening Remarks

Ann Richmond, Ph.D., Associate Professor of Cell Biology,  
Vanderbilt University School of Medicine

9:10 Direct Clinical Applications of Chemokines

Ted Moilne, Ph.D., Vice President Research, Regenex Corporation

While many chemokines possess inflammatory properties and are targets for the development of antagonists, several chemokines, such as PF-4, possess activity profiles that support their direct clinical application. In the case of PF-4, its ability to safely reverse the anticoagulant properties of heparin *in vivo* has led to extensive clinical testing and development for this use following cardiac surgical procedures. The ability of PF-4 and other chemokines to specifically inhibit endothelial cell migration and proliferation provided the rationale for testing of these agents as clinically useful angiogenesis inhibitors in cancer and Kaposi's sarcoma patients. Other chemokines, including enhanced activity mutants, produce effects on primitive myeloid cell lineages that offer novel strategies for protecting these cells from the cytotoxic effects of chemotherapy and for mobilizing cells for stem cell transplant. Suppressive effects in animal models of allergen-associated pulmonary hyperresponsiveness suggest further applications of chemokines in the treatment of asthma. In addition to these therapeutic and prophylactic applications, the selective association of these proteins with specific cell types offers parallel diagnostic, and potentially prognostic, uses of the chemokines, and a demonstration of the ability of PF-4 to selectively inhibit actively proliferating neovascuclite *in vivo* will be presented.